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Abstract
Background: In recent years, the clinical evidence of the controlling nutritional status (CONUT) score has increased
in patients with gastrointestinal cancers. The purpose of this systematic review and meta-analysis was to investigate
the association between the preoperative CONUT score and outcomes in patients undergoing gastrectomy for
gastric cancer (GC).
Methods: A systematic literature search for studies reporting the prognostic impact of the CONUT score in patients
with GC was conducted. Meta-analyses of survival, postoperative outcomes, and postoperative clinico-pathological
parameters were conducted.
Results: Five studies with 2482 patients were found to be eligible and subsequently reviewed and analyzed. The
CONUT score was significantly associated with overall survival (HR 1.85, 95%CI 1.38–2.48, P < 0.001), cancer-specific
survival (HR 2.56, 95%CI 1.24–5.28, P = 0.01) and recurrence/relapse-free survival (HR 1.43, 95%CI 1.12–1.82, P = 0.004).
Moreover, the CONUT score was associated with the incidence of postoperative complications (OR 1.39, P = 0.003)
and mortality (OR 6.97, P = 0.04), and clinico-pathological parameters (T factor [OR 1.75, P < 0.001], N factor [OR
1.51, P < 0.001], TNM stage [OR 1.73, P < 0.001], and microvascular invasion [OR 1.50, P = 0.006]), but not with
tumor differentiation (OR 0.85, P = 0.13).
Conclusions: The preoperative CONUT score is an independent prognostic indicator of survival and postoperative
complications, and is associated with clinico-pathological parameters in patients with GC.
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Background
The controlling nutritional status (CONUT) score was
developed several years as an accessible nutritional
screening tool for evaluating patients’ nutritional status
calculated from serum albumin level, total cholesterol
level, and total lymphocyte count [1]. As the prognostic
role of nutritional status has been reported in the disease
progression and survival of cancer patients [2], interest
in the CONUT score increased. This led to recent re-
views that showed the clinical evidence of the CONUT
score on long-term prognosis in patients with gastro-
intestinal and hepato-pancreato-biliary cancer [3, 4]. In
addition to these long-term associations, our research
group has recently reported the association between the
CONUT score and postoperative complication risk in
gastrointestinal and hepato-pancreato-biliary surgical
oncology [5, 6]. To date, however, published reviews did
not restrict search strategy to organ-specific cancers or
procedures. Different cancers and procedures are associ-
ated with different surgical complication risk and cancer
prognosis. Therefore, the impact of the CONUT score
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in specific in cancers forming in specific organs, treated
with specific surgical techniques, should be examined.
The impact of the CONUT score on outcome in
patients with gastric cancer (GC) was first reported in
2018 [7]. After that, several studies on the CONUT
score in GC have been published [8, 9]. However, results
of these studies are reported differently, using different
cut-off values of the CONUT score. To date, the impact
of the CONUT score on outcomes has not yet been
systematically examined in patients with GC.
The aim of the present study was to investigate the as-
sociation between the CONUT score and outcomes in-
cluding short-term and long-term prognosis in patients
following gastrectomy for GC. Moreover, we explored
the significance of the CONUT score on postoperative
clinico-pathological parameters in patients with GC.
Methods
The present study was reported according to the Pre-
ferred Reporting Items for Systematic Reviewers and
Meta-Analyses (PRISMA) guidelines [10]. Details of the
systematic literature search strategy have been reported
previously [5]. A systematic literature search was con-
ducted on the 15th of January 2019 to identify all
available manuscripts that report the association be-
tween the CONUT score and outcomes in patients with
GC (Additional file 1: Table S1). Inclusion criteria were
the following: (1) patients undergoing curative resection
for GC; (2) in whom the CONUT score was assessed
preoperatively; and for whom (3) postoperative out-
comes including short-term outcomes and long-term
survival were reported.
After removing duplicate records, abstracts and full-
text articles were screened independently by two investi-
gators (KT and PD). The extracted data included year
and country of study publication, study type, patient
information, pathological finding, cut-off value of the
CONUT score, and short-term and long-term outcomes.
The Newcastle-Ottawa quality assessment scale for
cohort studies was used to assess the methodological
quality of each studies [11]. As previously, studies with a
total score of 6 or higher were considered high-quality
studies [12].
The primary endpoint of this report was long-term sur-
vival, and included overall survival (OS), cancer-specific
survival (CSS) and recurrence free survival (RFS). Second-
ary endpoints were short-term outcomes: postoperative
morbidity, mortality and postoperative clinico-pathological
parameters. Postoperative complications and pathological
findings were evaluated based on the definition proposed in
each study. The postoperative clinico-pathological parame-
ters included tumor (T) stage (T1/2 versus T3/4), lymph
node (N) stage (N0/1 versus N2/3), TNM stage (stage I/II
versus III), tumor differentiation (well differentiated versus
poorly differentiated), and microvascular invasion (absent
versus present).
Statistical analysis
Analyses were performed using R 3.5.4 (cran.r-project.
org) and Review Manager 5.3 (Cochrane Collaboration,
2014). The pooled hazard ratios (HR) and odds ratios
(OR) with 95% confidence interval (95%CI) were
calculated for the different outcomes using the inverse
variance method. Heterogeneity among studies was
quantified by calculating the I2 values and a Χ2 test was
conducted, with P < 0.05 being statistically significant
and I2 values of 50% or more indicating the presence of
heterogeneity. We conducted random effects meta-ana-
lyses for all outcomes, as studies were heterogeneous
with regards to population and received treatments.
Funnel plots were utilized in order to evaluate potential
publication bias for all reviewed outcomes.
Results
The literature search according to the PRISMA guidelines
identified five studies as shown in Fig. 1 [7–9, 13, 14]. Five
articles with 2482 patients were included. All studies were
retrospective series from Asian countries, more particu-
larly Japan and China in 2018 (Table 1). Four [7–9, 14]
were single center studies and one [13] was multi-center
study. Different cut-off values of the CONUT score were
used in each study. All studies focused on long-term sur-
vival such as OS, CSS, or RFS. Median follow-up period
ranged between 36 and 61months. The quality assess-
ment of the included studies showed that all studies were
considered to be high-quality (Additional file 1: Table 2).
Funnel plots of OS, CSS, and RFS demonstrated no obvi-
ous asymmetry (Additional file 1: Figure S1). Regarding
surgical procedures, 723 out of 2066 (35.0%) were total
gastrectomy, and 1343 (65.0%) were partial or subtotal
gastrectomy [8, 9, 13, 14]. In contrast, 73.6% (1520 of
2066) were open procedure and 26.4% (546 of 2066) were
laparoscopic procedure.
Table 2 details the correlation between the CONUT
score and the different outcomes of interest in the differ-
ent studies. The results of meta-analysis for the primary
and secondary endpoints in terms of high CONUT
group versus low CONUT group are shown in Fig. 2
and Table 3 respectively.
The impact of the CONUT score on OS was investi-
gated in four studies. All studies reported 5-year OS in
the high CONUT group was significantly poorer than
that in the low CONUT group [7, 8, 13, 14]. The multi-
variable analysis of each study revealed that the CONUT
score was as an independent predictor associated with
OS. Our meta-analysis within these studies comprising
1785 patients demonstrated that the CONUT score was
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Fig. 1 PRISMA 2009 Flow Diagram
Table 1 Literatures investigation the effects of the CONUT score in patients undergoing curative resection for gastric cancer
Study Year Country Study design Number
(Male)
Tumor
stage
Cut-off for high
CONUT group
Prevalence of high
CONUT score
End points Follow-up
(median, months)
Qualitya
Kuroda
[7]
2018 Japan Retrospective
Single center
416
(267)
I: 275
II: 81
III: 60
≥4 14.9% OS
CSS
RFS
Complications
61.2 6
Zheng [8] 2018 China Retrospective
Single center
532
(403)
I: 165
II: 123
III: 244
0–1 (normal)
2–4 (light)
≥5 (moderate or
severe)
54.7%
34.4%
10.9%
OS
RFS
60 7
Liu [9] 2018 China Retrospective
Single center
697
(457)
II: 194
III: 503
≥3 31.1% CSS
Complications
36 6
Ryo [13] 2018 Japan Retrospective
Multi-center
626
(435)
II: 281
III: 345
≥2 46.2% OS
RFS
Complications
49.2 7
Suzuki
[14]
2018 Japan Retrospective
Single center
211
(141)
I: 132
II: 53
III: 26
≥5 17.1% OS
CSS
Complications
47 6
aScore from a maximum of 9 evaluated by the Newcastle–Ottawa quality assessment scale for cohort studies. [11]
CONUT Controlling nutritional status, OS Overall survival, CSS Cancer-specific survival, RFS Recurrence/relapse-free survival
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associated with OS (HR 1.85, 95%CI 1.38–2.48, P <
0.001, I2 = 54%, P = 0.09) (Fig. 2a).
The relationship between the CONUT score and CSS
was reported in three studies [7, 9, 14]. In two studies
the CONUT score was an independent prognostic factor
for CSS in the multivariable analysis [9, 14], however
one study showed no significant association between the
CONUT score and CSS [7]. Meta-analysis of outcomes
within these studies identified an association between
the CONUT score and CSS (HR 2.56, 95%CI 1.24–5.28,
P = 0.01, I2 = 63%, P = 0.07, n = 1324) (Fig. 2b).
Three studies [7, 8, 13] reported the influence of the
CONUT score on RFS. The multivariable analysis of
each study showed no significant association between
the CONUT score and RFS. However, our meta-ana-
lysis indicated that the CONUT score was associated
with RFS (HR 1.43, 95%CI 1.12–1.82, P = 0.004, I2 =
16%, P = 0.30, n = 1574) (Fig. 2c).
The effect of the CONUT score on postoperative over-
all complications was reported in four studies, demon-
strating no significant association between the CONUT
score and postoperative complications [7, 9, 13, 14]. One
study conducted the multivariable analysis showing that
high CONUT score was an independent risk factor for
procedure-unrelated infectious morbidity (OR 2.36, 95%CI
0.99–5.40, P = 0.046) [14]. The two studies reported the no
correlation between the CONUT score and postoperative
mortality [13, 14]. In meta-analysis, the CONUT score was
found to be associated with the incidence of postoperative
overall complications (OR 1.39, 95%CI 1.12–1.74, P =
0.003, I2 = 0%, P = 0.56, n = 1950) and mortality (OR 6.97,
95%CI 1.10–41.7, P = 0.04, I2 = 0%, P = 0.56, n = 837).
Regarding the postoperative clinico-pathological parame-
ters, the CONUT score was associated with T stage (OR
1.75, 95%CI 1.30–2.34, P < 0.001, I2 = 0%, P = 0.47, n =
1739), N stage (OR 1.51, 95%CI 1.20–1.90, P < 0.001, I2 =
5%, P = 0.35, n = 1739), TNM stage (OR 1.73, 95%CI 1.29–
2.33, P < 0.001, I2 = 55%, P = 0.07, n = 2482), and micro-
vascular invasion (OR 1.50, 95%CI 1.02–2.00, P = 0.006,
I2= 0%, P = 0.64, n = 1645). However, no significant associ-
ation was found in tumor differentiation (OR 0.85, 95%CI
0.68–1.05, P = 0.13, I2 = 16%, P = 0.31, n = 2482).
Discussion
The present study suggests that the CONUT score is a
potential nutritional screening tool for the prediction of
the outcomes including not only long-term and short-
term outcomes, but also clinico-pathological parameters
in patients undergoing gastrectomy for GC. To the best
of our knowledge, this systematic review and meta-ana-
lysis is the first to investigate the prognostic impact of
the CONUT score on outcomes in patients with GC.
The present study demonstrated that the CONUT score
was associated with long-term prognosis and the
incidence of postoperative complications and mortality
after gastrectomy for GC. Furthermore, we found the
Table 2 Studies reporting the effects of the CONUT score on outcomes in patients with gastric cancer
Study Overall
complication
Mortality Reccurence/relapse-free
survival
Cancer-specific survival Overall survival
Kuroda
[7]
37.1 vs 27.7% (P =
0.133)
n.a. 5-year: 77.8 vs 90.6% (P = 0.017)
HR 2.63 (1.16–5.98),
P = 0.021**
5-year: 82.3 vs 94.0% (P = 0.019)
HR 4.13 (1.62–10.55), P = 0.003**
5-year: 43.8 vs 84.8% (P < 0.001)
HR 2.72 (1.74–4.25), P < 0.001*
Zheng
[8]
n.a. n.a. 5-year: 51.6 vs 70% (Light vs normal)
(P < 0.001)
HR 1.376 (1.005–1.884)*
55.2 vs 70% (Moderate vs normal)
(P = 0.017)
HR 1.154 (0.726–1.836),
P = 0.137*
n.a. 5-year: 53.2 vs 71.4%
(Light vs normal) (P < 0.001)
HR 1.360 (0.984–1.879)*
54.5 vs 71.4%
(Moderate vs normal)
(P = 0.006)
HR 1.266 (0.753–2.126),
P = 0.173*
Liu [9] 26.7 vs 21.9% (P =
0.161)
n.a. n.a. 5-year: 39.3 vs 55.5% (P < 0.001)
HR 1.553 (1.080–2.232),
P = 0.017*
n.a.
Ryo
[13]
31.5 vs 26.4% 90-day:
1.4 vs
0.3%
HR 1.33 (0.98–1.81), P = 0.0637** n.a. HR 1.74 (1.26–2.41), P = 0.0007*
Suzuki
[14]
55.5 vs 36%
(P = 0.09)
Infectious: 44.4 vs 25.7%
(P = 0.08)
OR 2.36 (0.99–5.40),
P = 0.046*
3 vs 0%
(P = 0.09)
n.a. 5-year: 64, 75 vs 33% (stage II/III;
normal, light vs moderate and
severe) (P = 0.003)
HR 3.75 (1.30–10.43), P = 0.015*
5-year: 88, 76 vs 51% (stage I;
normal, light vs moderate and
severe) (P = 0.044)
64, 53 vs 24% (stage II/III;
normal, light vs moderate and
severe) (P = 0.007)
HR 2.12 (1.18–3.69), P = 0.012*
Data are shown for high CONUT group versus low CONUT group unless otherwise indicated. OR and HR is shown with 95% confidence interval. *Multivariable
analysis. **Univariate analysis
CONUT Controlling nutritional status, HR Hazard ratio, OR Odds ratio, n.a., not available
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significant association between the CONUT score and
clinico-pathological parameters.
A recent study has shown the CONUT score could be
a prognostic indicator of long-term survival in gastro-
intestinal cancer patients after surgery, however this ana-
lysis included only one article in patients with GC [4].
Therefore, the authors suggested to explore the prognos-
tic value of the CONUT score specifically for the differ-
ent included cancers. In contrast, the prognostic
nutritional index (PNI), calculated based on the serum
albumin level and total lymphocyte count, has well
described correlations with short-term and long-term
outcomes in the literature [15]. In a recent meta-ana-
lysis, the prognostic significance of the PNI for
prognosis in patients with cancers was confirmed [16].
Furthermore, the significance of PNI in patients with
GC has been investigated in a review with ten studies
describing 3396 patients [17]. Several studies have re-
ported that the CONUT score was a better prognostic
index of short-term and long-term outcome than the
PNI in various cancers [6, 9, 13, 18–20]. Furthermore,
the CONUT score has been reported to be the most
accurate predictor compared with other prognostic fac-
tors such as the neutrophil to lymphocyte ratio, modified
Glasgow Prognostic Score, tumor stage, and immune-
nutritional factors [7, 20]. Our findings confirm clinical
significance of the CONUT score in patients with GC.
In the present study, we analyzed the results of five
published retrospective studies on subjects with the
CONUT score and outcomes of GC (Table 2).
Fig. 2 Forest plots demonstrating primary endpoint in terms of high CONUT group versus low CONUT group. a Overall survival; b Cancer-specific
survival; and c Recurrence/relapse-free survival
Table 3 Secondary endpoints in terms of high CONUT group versus low CONUT group
Variables No. of studies No. of patients OR 95%CI P value I2 (%) Heterogeneity P value
Overall complications 4 1950 1.39 1.12–1.74 0.003 0 0.56
Mortality 2 837 6.79 1.10–41.7 0.04 0 0.56
T3/4 3 1739 1.75 1.30–2.34 < 0.001 0 0.47
N2/3 3 1739 1.51 1.20–1.90 < 0.001 5 0.35
Stage III 5 2482 1.73 1.29–2.33 < 0.001 55 0.07
Poor differentiation 5 2482 0.85 0.68–1.05 0.13 16 0.31
Microvascular invasion 3 1645 1.50 1.02–2.00 0.006 0 0.64
CONUT Controlling nutritional status, OR Odds ratio, 95%CI, 95% confidence interval
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Although some studies showed the association between
the CONUT score and OS, the relationship between
the CONUT and CSS, RFS, and the risk of postopera-
tive complication remained controversial because of
differences in reported outcomes (Table 3). Moreover,
the significance of the CONUT score on clinico-patho-
logical parameters was unknown. The present meta-
analysis indicated that patients with high CONUT score
had a significantly worse OS, CSS and RFS, and had a
higher incidence of postoperative complications and
mortality in patients with GC. Furthermore, high
CONUT score was significantly associated with more
advanced tumor characteristics including advanced T
and N stage, advanced TNM stages, and positive micro-
vascular invasion.
The biological mechanism regarding the association
between the CONUT score and outcomes has not been
fully investigated in GC patients, however there were
several reasons to explain why a high CONUT score was
associated with poor outcomes in GC. First, each of
components of the CONUT score has been reported to
be related to outcomes in patients with GC. Serum
albumin is a major indicator of nutritional status and
systematic inflammation and is reported to be associated
with the survival in patients with GC [21, 22]. Serum
cholesterol level has been reported to correlate with
tumor progression and survival in various gastrointes-
tinal cancers [23–25]. Total lymphocyte, an indicator of
immune and nutritional status in cellular and antiviral
immunity, is reported to be related with the prognosis in
GC [26]. Secondly, our results suggested that high
CONUT score was associated with more advanced
tumor characteristics, including advanced T and N stage,
advanced TNM stages, and positive microvascular inva-
sion. Although the association between the PNI and the
extent of tumor progression has been reported [17], it
remains unknown whether the results of the CONUT
score or PNI were a cause or a consequence of tumor
progression. Finally, emerging evidence has shown that
patients’ frailty evaluated by sarcopenia was associated
with the prognosis and the risk of postoperative compli-
cations in gastrointestinal surgical oncology [27, 28].
Zheng et al. reported that sarcopenia was a more object-
ive predictor than the CONUT score of the survival in
GC, although this finding must be confirmed by a large
prospective study [8].
We acknowledge several limitations of the present
study. The number of included studies in the meta-ana-
lysis was relatively small. All the included studies were
retrospective cohort study from Asian countries, there-
fore it remains unknown whether our results can be ap-
plied to Western populations. Future studies should be
validated in Western population. Different cut-off values
were used in each studies. Although the original
CONUT score article described four categories, the cut-
off values of the CONUT score used in the literature dif-
fers between and different cancers [3, 4]. Finally, the na-
ture of the relationship between the CONUT score and
outcomes is not fully elucidated in patients with GC.
Therefore, further well-designed studies are needed to
identify the impact of the CONUT score on outcomes
and to determine the most appropriate cut-off value to
predict the survival and complication risks in patients
with GC.
In conclusion, the present study suggests that the pre-
operative CONUT score could be an indicator to predict
the survival, postoperative complications and postopera-
tive clinico-pathological parameters in patients following
gastrectomy for GC. This review highlights the need for
comprehensive assessment of the CONUT score in clin-
ical practice as it would be helpful for decision-making
in patients with GC. Evaluating the CONUT score is
easy and practical to estimate the prognosis and compli-
cation risks, therefore the CONUT score should be eval-
uated preoperatively in patients undergoing gastrectomy
for GC.
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